Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Aim of the trial is to evaluate the safety and efficacy of sintilimab and pegaspargase in
combination with pegaspargase for the initial treatment of previously untreated patients with
limited stage NK/T cell lymphoma.All eligible patients will be treated with sintilimab
combined with pegaspargase administered every 3 weeks for 4 cycles followed by standard
radiotherapy with or without concurrent sintilimab and pegaspargase administered every 3
weeks. After radiotherapy, patients with complete remission with positive plasma EBV-DNA or
partial response will continue with sintilimab maintenance up to 2 years.